Archive - April 2025
Behind the Headlines Episode 15–Neuroscience, Weight-Loss Drugs, and Tariffs
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
STAT+: Research grants as political ammo; Death to dyes?
The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs
Regeneron, Sanofi Get FDA Approval for Dupixent to Treat Chronic Spontaneous Urticaria
New CDMO Meribel Pharma Solutions Launches with 13 Sites in Europe
Using RWD to Create Personalized Engagement
STAT+: Women’s Health Initiative, known for hormone therapy trials, to lose federal funding